By Fineline Cube 
China-based Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) has announced the initiation of a Phase I clinical study for its investigational drug NH280105, an oral Lp-PLA₂ inhibitor for the treatment of Alzheimer’s disease (AD). The first subject has been enrolled and dosed, marking a significant milestone in the development of this novel therapeutic candidate.
Mechanism of Action
NH280105 targets Lp-PLA₂ (lipoprotein-associated phospholipase A₂), an enzyme linked to low-density lipoprotein (LDL) that plays a critical role in promoting inflammation in cardiovascular and neurological tissues. By inhibiting Lp-PLA₂, NH280105 effectively reduces inflammation and repairs the physiological function of the blood-brain barrier (BBB). This mechanism helps reduce the deposition of pathological biomarkers such as Aβ plaques, potentially improving cognitive function in patients with Alzheimer’s disease. Its unique approach positions NH280105 as a promising new option in the evolving landscape of AD therapy.
Clinical Study Design
The Phase I study, conducted at CMAX in Australia, is designed to evaluate the safety, tolerability, and pharmacokinetics of NH280105 in healthy adult subjects. The trial will assess both single and multiple oral doses and explore the effects of food interactions on the drug’s absorption and systemic exposure. These data will provide essential support for the drug’s subsequent clinical development stages.-Fineline Info & Tech